Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 357.5 EUR 0.85% Market Closed
Market Cap: 3B EUR

Relative Value

The Relative Value of one VIRP stock under the Base Case scenario is 433.56 EUR. Compared to the current market price of 357.5 EUR, Virbac SA is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VIRP Relative Value
Base Case
433.56 EUR
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
87
vs Industry
54
Median 3Y
1.9
Median 5Y
2
Industry
2.6
Forward
2
vs History
87
vs Industry
27
Median 3Y
19.1
Median 5Y
19.2
Industry
21.8
Forward
18.8
vs History
66
vs Industry
31
Median 3Y
17
Median 5Y
18.8
Industry
16.5
vs History
0
vs Industry
33
Median 3Y
30.4
Median 5Y
30.1
Industry
22.8
vs History
61
vs Industry
30
Median 3Y
2.7
Median 5Y
3
Industry
2.3
vs History
84
vs Industry
52
Median 3Y
1.9
Median 5Y
2
Industry
2.8
Forward
2.1
vs History
73
vs Industry
61
Median 3Y
3.3
Median 5Y
3.9
Industry
5.4
vs History
87
vs Industry
33
Median 3Y
9.6
Median 5Y
10.4
Industry
12.7
Forward
10.4
vs History
87
vs Industry
33
Median 3Y
12.2
Median 5Y
13.1
Industry
16.3
Forward
13.2
vs History
61
vs Industry
31
Median 3Y
16.2
Median 5Y
17.9
Industry
15.1
vs History
46
vs Industry
22
Median 3Y
31.1
Median 5Y
33
Industry
17.7
vs History
60
vs Industry
38
Median 3Y
2
Median 5Y
2.2
Industry
2

Multiples Across Competitors

VIRP Competitors Multiples
Virbac SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Virbac SA
PAR:VIRP
3B EUR 1.7 6.3 5 5.6
US
Eli Lilly and Co
NYSE:LLY
962.7B USD 16.2 52.3 35.1 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
467.7B USD 5.1 18.6 15.3 19.8
CH
Roche Holding AG
SIX:ROG
231.2B CHF 3.8 24.5 11.1 12.6
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 29.3 107.8 157.7
CH
Novartis AG
SIX:NOVN
200.9B CHF 4.5 17.5 11.1 14.4
US
Merck & Co Inc
NYSE:MRK
227.5B USD 3.5 12 8.6 10.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
147.1B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
FR
Virbac SA
PAR:VIRP
Average P/E: 21
6.3
11%
0.6
US
Eli Lilly and Co
NYSE:LLY
52.3
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.6
29%
0.6
CH
Roche Holding AG
SIX:ROG
24.5
29%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.3
38%
0.8
CH
Novartis AG
SIX:NOVN
17.5
18%
1
US
Merck & Co Inc
NYSE:MRK
12
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
7%
2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBITDA: 398
5
6%
0.8
US
Eli Lilly and Co
NYSE:LLY
35.1
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.3
8%
1.9
CH
Roche Holding AG
SIX:ROG
11.1
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
107.8
10%
10.8
CH
Novartis AG
SIX:NOVN
11.1
6%
1.9
US
Merck & Co Inc
NYSE:MRK
8.6
7%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBIT: 1 707.7
5.6
6%
0.9
US
Eli Lilly and Co
NYSE:LLY
37.7
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.8
14%
1.4
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
157.7
22%
7.2
CH
Novartis AG
SIX:NOVN
14.4
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.2
9%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
6%
1.9
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1